Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.87M | 5.00M | 4.64M | 4.08M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.14M | 15.52M | 14.39M | 9.95M | 9.58M |
| Operating Income | -16.14M | -15.52M | -14.39M | -9.95M | -9.58M |
| Income Before Tax | -14.47M | -13.91M | -12.76M | -8.93M | -9.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.47M | -13.91M | -12.76M | -8.93M | -9.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.47M | -13.91M | -12.76M | -8.93M | -9.20M |
| EBIT | -16.14M | -15.52M | -14.39M | -9.95M | -9.58M |
| EBITDA | -16.00M | -15.39M | -14.27M | -9.82M | -9.46M |
| EPS Basic | -0.66 | -0.63 | -0.58 | -0.80 | -5.17 |
| Normalized Basic EPS | -0.41 | -0.40 | -0.40 | -0.54 | -3.23 |
| EPS Diluted | -0.66 | -0.63 | -0.58 | -0.80 | -5.17 |
| Normalized Diluted EPS | -0.41 | -0.40 | -0.40 | -0.54 | -3.23 |
| Average Basic Shares Outstanding | 22.08M | 21.97M | 21.92M | 11.09M | 1.78M |
| Average Diluted Shares Outstanding | 22.08M | 21.97M | 21.92M | 11.09M | 1.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |